Back to Results

A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess Effect, Safety, Tolerability and PK of Multiple SC Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for IV Dosing as an Alternative Route of Administration

Interested in this Trial?

Contact Us

Trial Status Terminated

Trial Identifier

NCT01910649

Condition

Duchenne Muscular Dystrophy, Muscular Dystrophies

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

The purpose of the extension phase of this study is to determine whether Drisapersen is effective in the treatment of boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 skipping.

Eligibility Criteria

Birth Sex

Male

Age

5 Years to 16 Years

Healthy Volunteers

No

Drug/Treatment:

Drisapersen

Phase:

Phase 2

Study Type:

Interventional

Number of Participants:

12

Study Started:

2008-03

Study Updated:

2016-11-06

Inclusion Criteria

  • Boys aged between 5 and 16 years inclusive.
  • Duchenne muscular dystrophy resulting from a mutation correctable by treatment with PRO051.
  • Not ventilator dependent.
  • Life expectancy of at least six months.
  • No previous treatment with investigational medicinal treatment within six months prior to the study.
  • Willing and able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria

  • Aberrant RNA splicing and/or aberrant response to PRO051, detected by in vitro PRO051 assay during screening.
  • Known presence of dystrophin in 5% of fibers in a pre-study diagnostic muscle biopsy.
  • Severe muscle abnormalities defined as increased signal intensity in >50% of the tibialis anterior muscle at MRI.
  • FEV1 and/or FVC <60% of predicted.
  • Current or history of liver or renal disease.
  • Acute illness within 4 weeks prior to treatment (Day 1) which may interfere with the measurements.
  • Severe mental retardation which in the opinion of the investigator prohibits participation in this study.
  • Severe cardiac myopathy which in the opinion of the investigator prohibits participation in this study.
  • Need for mechanical ventilation.
  • Creatinine concentration above 1.5 times the upper limit of normal (age corrected).
  • Serum ASAT and/or ALAT concentration(s) which suggest hepatic impairment.
  • Use of anticoagulants, antithrombotics or antiplatelet agents.
  • Subject has donated blood less than 90 days before the start of the study.
  • Current or history of drug and/or alcohol abuse.
  • Participation in another trial with an investigational product

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our active clinical trials

*required fields

"*" indicates required fields

Please select the trial that you are interested in from the dropdown below. Note that this list only includes currently active trials. If you cannot find the trial you are seeking, please enter the study identifier and title in the comments box below, along with any other details you would like us to know to help address your inquiry.
Consent*
Consent*
For more Information about BioMarin's privacy obligations or to exercise your privacy rights, please visit BioMarin's Data Privacy Center.
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

What’s Next?

Visit the following links to learn more about clinical trials.

Discuss this trial with your care team.

You may wish to print this page to share the details with your healthcare providers and discuss whether you may be eligible.

Print

Get in touch.

Contact Us